| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expenses | 4,576,389 | 4,212,918 | ||
| General and administrative expenses | 3,563,753 | 3,410,433 | ||
| Total operating expenses | 8,140,142 | 7,623,351 | ||
| Loss from operations | -8,140,142 | -7,623,351 | ||
| Interest income | 281,109 | 333,624 | ||
| Interest expense | 1,150,378 | 2,144,481 | ||
| Interest income (expenses), net | -869,269 | -1,810,857 | ||
| Loss before income taxes | -9,009,411 | -9,434,208 | ||
| Benefit from income taxes | 0 | 0 | ||
| Net loss | -9,009,411 | -9,434,208 | ||
| Net loss per share, basic (in dollars per share) | -0.19 | -0.21 | ||
| Net loss per share, diluted (in dollars per share) | -0.19 | -0.21 | ||
| Weighted average common shares outstanding, basic (in shares) | 46,869,531 | 45,902,502 | ||
| Weighted average common shares outstanding, diluted (in shares) | 46,869,531 | 45,902,502 | ||
PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (PDSB)